Mereo Biopharma Group (MREO) investor relations material

Executive summary

• Focused on developing therapeutics for rare diseases, with late-stage candidates setrusumab (osteogenesis imperfecta) and alvelestat (AATD-LD), and an early-stage program vantictumab (ADO2).

• Advanced regulatory engagement for setrusumab in pediatric osteogenesis imperfecta following Phase 3 data analysis, with ongoing discussions for approval pathways.

• Active partnership discussions for alvelestat, aiming for rapid Phase 3 initiation in AATD-LD upon deal closure.

• Vantictumab development progressing with partner āshibio, targeting Phase 2 trial initiation in ADO2 in H2 2026.

• Strategy centers on acquiring and developing rare disease assets with significant prior investment and data.

Financial highlights

• Net loss for Q1 2026 was $6.7 million, a significant improvement from $12.9 million in Q1 2025, reflecting lower operating loss and a $1.6 million foreign currency gain.

• R&D expenses increased to $4.7 million (from $3.9 million), mainly due to setrusumab costs, while G&A decreased to $4.0 million (from $7.3 million) year-over-year, driven by ADR reimbursements and delayed pre-commercial investments.

• Cash and cash equivalents at March 31, 2026 were $36.2 million, down from $41.0 million at year-end 2025.

• Total shareholders’ equity was $34.1 million at March 31, 2026.

• Net cash used in operating activities for Q1 2026 was $4.3 million, down from $8.3 million in Q1 2025.

Outlook and guidance

• Cash runway expected to extend into mid-2027 under current plans, supporting key clinical milestones; additional funding will be needed for full development and commercialization.

• Plans to fund operations through a mix of non-dilutive sources, equity, or debt financing.

• Ongoing focus on advancing setrusumab and alvelestat, with preparation for potential commercialization of setrusumab in Europe.

• Guidance remains unchanged based on current operational plans.